KKR Acquires Bushu Pharmaceuticals from BPEA EQT

Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation

February 7, 2025

Pharmaceuticals

Bain Capital has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) in a carve-out from Mitsubishi Chemical Group Corporation for approximately 510 billion JPY (about $3.3 billion). The deal, led by Bain’s Private Equity teams in Asia and North America together with its Life Sciences group, will create an independent, standalone Japanese pharma platform focused on drug discovery and development across immunology, CNS, vaccines, diabetes and other priority areas; the transaction is expected to close in Q3 2025.

Shionogi Inc. Acquires Qpex Biopharma, Inc.

June 26, 2023

Pharmaceuticals

Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.

EQT Acquires Baring Private Equity Asia

March 16, 2022

Financial Services

EQT AB has agreed to acquire Baring Private Equity Asia (BPEA) in a €6.8bn transaction comprising 191.2m new EQT shares and ~€1.5bn–€1.6bn in cash, creating a scaled Pan-Asian active ownership platform rebranded as BPEA EQT Asia. The combination brings BPEA's private equity and real estate capabilities into EQT's global platform, with BPEA CEO Jean Eric Salata to lead the combined Asian business.

Bora Pharmaceuticals Acquires Upsher-Smith Laboratories

August 5, 2025

Pharmaceuticals

Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.

Torrent Pharmaceuticals Acquires Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR

June 29, 2025

Pharmaceuticals

Torrent Pharmaceuticals has agreed to acquire a controlling stake in J. B. Chemicals & Pharmaceuticals from KKR at an equity valuation of INR 25,689 crore, purchasing a 46.39% stake (with potential to aggregate to 49.19%) followed by a mandatory open offer and a planned merger. The deal strengthens Torrent's presence in the Indian pharmaceutical market and adds JB Pharma's CDMO and international capabilities to Torrent's platform.

Asahi Kasei Medical Acquires Bionova Scientific

April 14, 2022

Biotechnology

Asahi Kasei Medical agreed to wholly acquire Bionova Scientific, a Fremont, California-based biopharmaceutical CDMO that provides process development and GMP-compliant manufacturing services for next-generation antibody drugs. The acquisition, executed through a U.S. subsidiary, expands Asahi Kasei Medical's bioprocess and CDMO capabilities to better serve biologics developers and accelerate growth of its bioprocess business; closing is subject to regulatory clearances.